These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38340253)

  • 21. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
    Tan X; Liang Y; Gamble C; King A
    Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
    Furusawa S; Nomoto H; Yokoyama H; Suzuki Y; Tsuzuki A; Takahashi K; Miya A; Kameda H; Cho KY; Takeuchi J; Nagai S; Taneda S; Kurihara Y; Nakamura A; Atsumi T;
    Diabetes Obes Metab; 2024 Mar; 26(3):961-970. PubMed ID: 38073422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Campos C; Unger J
    Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
    Wang W; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    Ann Intern Med; 2024 Aug; 177(8):1016-1027. PubMed ID: 39074369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.
    Westerink J; Matthiessen KS; Nuhoho S; Fainberg U; Lyng Wolden M; Østergaard HB; Visseren F; Sattar N
    Diabetes Care; 2022 May; 45(5):1211-1218. PubMed ID: 35263432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
    Kashiwagi A; Shoji S; Kosakai Y; Yoshinaga Y; Rokuda M
    J Diabetes Investig; 2024 Mar; 15(3):374-387. PubMed ID: 38112598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
    Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
    Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
    Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
    Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
    Takahashi H; Asakawa K; Kosakai Y; Lee T; Rokuda M
    Diabetes Obes Metab; 2024 Mar; 26(3):997-1007. PubMed ID: 38086547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC;
    N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
    Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J
    Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
    Kim SC; Glynn RJ; Liu J; Everett BM; Goldfine AB
    Acta Diabetol; 2014 Dec; 51(6):1015-23. PubMed ID: 25311055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
    J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
    Thethi TK; Pratley R; Meier JJ
    Diabetes Obes Metab; 2020 Aug; 22(8):1263-1277. PubMed ID: 32267058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.